Intravenous bisphosphonates for postmenopausal osteoporosis
Numerous clinical studies have shown bisphoshonates (BPs) to be useful and cost-effective options for the fractures prevention and postmenopausal bone loss. The use of oral bisphoshonates is an established option for managment of osteoporosis in postmenopausal women, but many of them complaint from...
Main Author: | Peyman Mottaghi |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2010-01-01
|
Series: | Journal of Research in Medical Sciences |
Subjects: | |
Online Access: | http://www.jmsjournal.net/article.asp?issn=1735-1995;year=2010;volume=15;issue=3;spage=175;epage=184;aulast=Mottaghi |
Similar Items
-
Intravenous Bisphosphonates for Postmenopausal Osteoporosis
by: Peyman Mottaghi
Published: (2010-01-01) -
Osteoporosis in women in menopause/postmenopause: what to do?
by: E. V. Kulchavenya, et al.
Published: (2021-01-01) -
Open, Prospective, Multi-Center, Two-Part Study of Patient Preference with Monthly Ibandronate Therapy in Women with Postmenopausal Osteoporosis Switched From Daily or Weekly Alendronate or Risendronate-BONCURE: Results of Turkish Sub-Study
by: Nurten Eskiyurt, et al.
Published: (2012-04-01) -
First Indian prospective randomized comparative study evaluating adherence and compliance of postmenopausal osteoporotic patients for daily alendronate, weekly risedronate and monthly ibandronate regimens of bisphosphonates
by: Vishal R Tandon, et al.
Published: (2014-01-01) -
Long-Term Use of Bonviva® for the Treatment of Postmenopausal Osteoporosis: New Evidence
by: O.B. Yershova, et al.
Published: (2013-02-01)